{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T08:50:49Z","timestamp":1793523049365,"version":"4.5.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e9 d'Angers"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Polycythemia vera (PV) and Essential thrombcythemia (ET) are myeloproliferative neoplasms (MPNs) that can progress to secondary myelofibrosis, a complication associated with increased mortality. Circulating CD34-positive cells at diagnosis can be used to distinguish primary myelofibrosis from other MPNs with a threshold of 10\/\u00b5L. In this study, we evaluate the interest of serial CD34-positive cell quantifications during the follow-up of MPNs. We retrospectively include 180 patients with MPN (90 ET, 55 PV and 35 myelofibrosis) with at least two measurements of circulating CD34-positive cells. CD34-positive cell count showed an AUC of 0.901 for the diagnosis of post-ET\/PV myelofibrosis, with a sensitivity of 54.8%, a specificity of 99.5%, a PPV of 89.5% and a NPV of 96.3% for the threshold of 15 cells\/\u00b5L. The decreased sensibility could be explained by an impact of cytoreductive treatments. Then we focused on primary and secondary myelofibrosis (MF) and found that patients achieving partial or complete response (per IWG-MRT criteria) had lower CD34-positive cell levels. Finally, CD34-positive cell levels had a prognostic impact on overall survival in MF, a count\u2009\u2265\u2009100\/\u00b5L is predictive of a higher risk of death (HR\u2009=\u20092.9 [1.5\u20135.9]), independently of DIPSS classification. In conclusion, monitoring of circulating CD34-positive cells is valuable for evaluating both disease progression and prognosis in MPN patients.<\/jats:p>","DOI":"10.1007\/s00277-026-06755-1","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T01:18:58Z","timestamp":1768526338000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["CD34-positive circulating cells quantification during follow-up in myeloproliferative neoplasms"],"prefix":"10.1007","volume":"105","author":[{"given":"Marine","family":"Demoy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxence","family":"Bauvais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agathe","family":"Vely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Nicol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00e9mie","family":"Riou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hortense","family":"Le Jeanne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lien","family":"Bauduin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"Rambaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Genevi\u00e8ve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agathe","family":"Boussaroque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Christine","family":"Copin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Ugo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corentin","family":"Orvain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Luque Paz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"issue":"16","key":"6755_CR1","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1182\/blood.2022017578","volume":"141","author":"D Luque Paz","year":"2023","unstructured":"Luque Paz D, Kralovics R, Skoda RC (2023) Genetic basis and molecular profiling in myeloproliferative neoplasms. Blood 141(16):1909\u201321","journal-title":"Blood"},{"issue":"16","key":"6755_CR2","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","volume":"124","author":"A Tefferi","year":"2014","unstructured":"Tefferi A, Guglielmelli P, Larson DR, Finke C, Wassie EA, Pieri L et al (2014) Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood 124(16):2507\u201313","journal-title":"Blood"},{"key":"6755_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.exphem.2020.05.004","volume":"86","author":"MR Hughes","year":"2020","unstructured":"Hughes MR, Canals Hernaez D, Cait J, Refaeli I, Lo BC, Roskelley CD et al (2020) A sticky wicket: Defining molecular functions for CD34 in hematopoietic cells. Exp Hematol juin 86:1\u201314","journal-title":"Exp Hematol juin"},{"issue":"7186","key":"6755_CR4","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/nature06685","volume":"452","author":"S M\u00e9ndez-Ferrer","year":"2008","unstructured":"M\u00e9ndez-Ferrer S, Lucas D, Battista M, Frenette PS (2008) Haematopoietic stem cell release is regulated by circadian oscillations. Nature mars 452(7186):442\u2013447","journal-title":"Nature mars"},{"issue":"12","key":"6755_CR5","doi-asserted-by":"publisher","first-page":"3249","DOI":"10.1182\/blood.V98.12.3249","volume":"98","author":"G Barosi","year":"2001","unstructured":"Barosi G, Viarengo G, Pecci A, Rosti V, Piaggio G, Marchetti M et al (2001) Diagnostic and clinical relevance of the number of circulating CD34(+) cells in myelofibrosis with myeloid metaplasia. Blood 98(12):3249\u201355","journal-title":"Blood"},{"issue":"10","key":"6755_CR6","first-page":"1123","volume":"88","author":"F Passamonti","year":"2003","unstructured":"Passamonti F, Vanelli L, Malabarba L, Rumi E, Pungolino E, Malcovati L et al (Oct2003) Clinical utility of the absolute number of circulating CD34-positive cells in patients with chronic myeloproliferative disorders. Haematologica 88(10):1123\u20131129","journal-title":"Haematologica"},{"issue":"11","key":"6755_CR7","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1007\/s00277-016-2784-x","volume":"95","author":"C Orvain","year":"2016","unstructured":"Orvain C, Luque Paz D, Dobo I, Cottin L, Le Calvez G, Chauveau A et al (2016) Circulating Cd34+ cell count differentiates primary myelofibrosis from other Philadelphia-negative myeloproliferative neoplasms: a pragmatic study. Ann Hematol 95(11):1819\u20131823","journal-title":"Ann Hematol"},{"issue":"4","key":"6755_CR8","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s00277-021-04672-z","volume":"101","author":"D Luque Paz","year":"2022","unstructured":"Luque Paz D, Cottin L, Lippert E, Robin JB, Bescond C, Genevieve F et al (2022) Different number of circulating CD34 + cells in essential thrombocythemia, prefibrotic\/early primary myelofibrosis, and overt primary myelofibrosis. Ann Hematol avr 101(4):893\u2013896","journal-title":"Ann Hematol avr"},{"issue":"7","key":"6755_CR9","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/ajh.26548","volume":"97","author":"F Mannelli","year":"2022","unstructured":"Mannelli F, Bencini S, Coltro G, Loscocco GG, Peruzzi B, Rotunno G et al (2022) Integration of multiparameter flow cytometry score improves prognostic stratification provided by standard models in primary myelofibrosis. American J Hematol juill 97(7):846\u2013855","journal-title":"American J Hematol juill"},{"issue":"3","key":"6755_CR10","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1111\/bjh.18526","volume":"200","author":"A Iurlo","year":"2023","unstructured":"Iurlo A, Galli N, Bucelli C, Artuso S, Consonni D, Cattaneo D (2023) Trend of circulating CD34+ cells in patients with myelofibrosis: Association with spleen response during ruxolitinib treatment. Br J Haematol f\u00e9vr 200(3):315\u2013322","journal-title":"Br J Haematol f\u00e9vr"},{"key":"6755_CR11","doi-asserted-by":"crossref","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al (2022) The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic\u00a0Neoplasms. Leukemia Juill 36(7):1703\u201119.","DOI":"10.1038\/s41375-022-01613-1"},{"issue":"15","key":"6755_CR12","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.1182\/blood-2010-06-293415","volume":"116","author":"F Passamonti","year":"2010","unstructured":"Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Cazzola M et al (2010) Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. Blood 116(15):2857\u20132858","journal-title":"Blood"},{"issue":"8","key":"6755_CR13","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1182\/blood-2013-03-488098","volume":"122","author":"A Tefferi","year":"2013","unstructured":"Tefferi A, Cervantes F, Mesa R, Passamonti F, Verstovsek S, Vannucchi AM et al (2013) Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood 122(8):1395\u20138","journal-title":"Blood"},{"issue":"Supplement 1","key":"6755_CR14","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1182\/blood-2024-205937","volume":"144","author":"JO Mascarenhas","year":"2024","unstructured":"Mascarenhas JO, Bose P, Hou HA, Homenda W, Ross D, Mohan SR et al (2024) Disease-Modifying Activity of Navtemadlin Correlates with Clinical Responses in a Randomized, Multicenter, Global Phase 3 Study (BOREAS) in JAK-Inhibitor Relapsed\/Refractory Myelofibrosis. Blood 144(Supplement 1):483\u2013483","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06755-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06755-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06755-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T01:50:51Z","timestamp":1784771451000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06755-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["6755"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06755-1","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,16]]},"assertion":[{"value":"10 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The present project has been registered by the French Data Protection Authority (Commission Nationale de l'Informatique et des Libert\u00e9s, ar20-0126v0) and received a favorable assessment from the ethics committee of Angers (number 2021\u2013003). Only data collected during routine care were used, and no patients declined participation in the research.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"21"}}